Recon: Pfizer to buy 8.1% stake in Valneva, Merck explores Seagen buyout

• COVID vaccine rollout for US children close after CDC panel vote (Reuters)
• Lawmakers ask GAO to probe pharmacy benefit managers over their role in drug pricing (STAT)
• Comparing the Pfizer and Moderna Covid vaccines for young children (STAT)
• Merck Explores Purchase of Biotech Seagen (WSJ)
• FDA advisors mostly agree that Acadia’s Nuplazid isn't effective at treating Alzheimer’s-related psychosis (Endpoints)

• Pfizer to buy 8.1 percent stake in French vaccines company Valneva (Reuters)
• EU drugs watchdog begins review of Moderna's variant COVID vaccine (Reuters)
• WHO panel backs use of Omicron-adapted vaccine as booster dose (Reuters)
• Greece Files Graft Lawsuit Against Novartis: Minister (Barron’s)
• FTC could sanction AstraZeneca over alleged collusion (The Korea Herald)
• China Tweaks On-Site Inspection Priorities As Registration Filings Soar (Endpoints)
• BioNTech chief calls for speedy ruling on Covid vaccines that target latest strains (FT)
• Global regulators work towards strengthening collaboration on observational research beyond COVID-19 pandemic (EMA)
• EMA Management Board: highlights of June 2022 meeting (EMA)

• Never forget that early vaccines came from testing on enslaved people (STAT)
• WTO's IP waiver for vaccines is out and the response is generally negative — from all sides (Endpoints)
• J&J inks clinical trial deal with Stand Up To Cancer, latest pharma to join cancer nonprofit study efforts (Endpoints)
• Pushing for top spot in Big Pharma, AbbVie lands a key approval for its blockbuster Skyrizi (Endpoints)
• More drug, fewer jabs: Novartis' Sandoz eyes EMA nod for high-concentration Humira copy (Fierce)
• Teetering on the brink, Clovis abandons an early approval for Rubraca (Endpoints)
• EU Proposes Changes To Labeling Of Investigational Drugs Under Clinical Trial Regulation (Pink Sheet)

• Morcellation Containment System Guidance Stresses Leak Detection, Prevention (MedtechInsight)
• The Pace Of Cyberattacks Is Accelerating. Can Regulators Keep Up? (MedtechInsight)
• MDR And IVDR – Similar Step Ups, Varying Commercial Impacts (MedtechInsight)

• Bristol Myers petitions the Supreme Court in a final bid to prove Gilead's Kite infringed on CAR-T patents (Endpoints)
• Generic Co. Asks Fed. Circ. To Undo Loss In Takeda IP Fight (Law360)